cas 3056-18-6|| where to buy (2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate

Produktname:(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate

IUPAC Name:[(2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-(2,6-dichloro-9H-purin-9-yl)oxolan-2-yl]methyl acetate

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM138799-5g	in stock	ǎǎŮ
CM138799-25g	in stock	ĳŮƴ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3056-18-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:3056-18-6; Molekulare Formel:C16H16Cl2N4O7; Schmelzpunkt:-; SMILES-Code:O=C(OC[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](N2C=NC3=C(Cl)N=C(Cl)N=C23)O1)C; Dichte:

: Katalognummer:CM138799; Molekulargewicht:447.23; Siedepunkt:555.3°C at 760 mmHg; Mdl-Nr.:MFCD02093101; Lagerung:Keep in inert atmosphere, store at 2-8°C.

: Nucleosides and Nucleotides; Nucleosides consist of a nucleotide and a five-carbon sugar, and a nucleotide consists of a nucleotide, a five-carbon sugar, and one or more phosphate groups.; nucleoside manufacturer; As a professional nucleoside manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

: Nucleosides; Nucleosides are glycosylamines that can be thought of as nucleotides without a phosphate group. A nucleoside consists simply of a nucleobase (also termed a nitrogenous base) and a five-carbon sugar (ribose or 2'-deoxyribose).

: Namodenoson; Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Namodenoson granted Orphan Drug and Fast track status from the FDA. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.